Categories AlphaGraphs, Earnings, Technology

Broadcom delivers mixed Q2 results; slashes FY19 revenue outlook

Broadcom (Nasdaq: AVGO) surpassed Q2 earnings estimates, while it missed on revenue targets. Shares of Broadcom slumped about 7% in the after-hours as the company cut down its revenue outlook for FY19. The company reported non-GAAP earnings of $5.21 per share on revenue of $5.52 billion for the second quarter of 2019. Analysts had expected the semiconductor maker to earn $5.18 per share on revenue of $5.69 billion.

On a GAAP basis, the San Jose, California-based firm reported earnings of $1.64 per share compared to earnings of $8.33 per share in the prior-year quarter.

For the fiscal year 2019, Broadcom cut down its revenue outlook to $22.5 billion from the prior outlook of $24.5 billion.

“We currently see a broad-based slowdown in the demand environment, which we believe is driven by continued geopolitical uncertainties, as well as the effects of export restrictions on one of our largest customers. As a result, our customers are actively reducing their inventory levels, and we are taking a conservative stance for the rest of the year,” said CEO Hock Tan.

Also Read: Global semiconductor revenues to fall this year on supply glut, China weakness

Among the peers, Analog Devices (ADI) last month reported lower earnings and revenues for its most recent quarter, hurt by muted demand in the consumer and industrial segments. Earnings decreased year-over-year to $1.36 per share on revenues of $1.53 billion. Earlier, Intel (INTC) posted flat revenues and higher earnings for the first quarter. Revenues matched the market estimates, while earnings beat.

Broadcom stock, which ended up 0.67% at $281.61 today, had advanced 11% since the beginning of 2019 and 7% in the past 52 weeks.

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips

Most Popular

IPO News: Monte Rosa Therapeutics will go public this week, here are a few things to know

Biotechnology company Monte Rosa Therapeutics is slated to go public this week. In a pandemic-ridden world, this industry is expanding at a healthy pace. The global biotechnology market is estimated

IPO News: What to look for when Elevation Oncology makes its Wall Street debut

The healthcare sector is going through a phase of consolidation, creating fresh opportunities for emerging companies in a market that is slowly recovering from the pandemic. Several pharmaceuticals firms have

American Airlines (AAL): Here’s what may or may not work for this airline stock

Shares of American Airlines Group (NASDAQ: AAL) have gained 42% since the beginning of this year and 50% over the past 12 months. Despite this, there is a mixed sentiment

Add Comment
Viewing Highlight